Mutant HRAS as novel target for MEK and mTOR inhibitors

HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized towar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiessling, Michael K., Curioni-Fontecedro, Alessandra, Samaras, Panagiotis, Atrott, Kirstin, Cosin-Roger, Jesus, Lang, Silvia, Scharl, Michael, Rogler, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747218/
https://www.ncbi.nlm.nih.gov/pubmed/26544513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747218/
https://www.ncbi.nlm.nih.gov/pubmed/26544513

Ejemplares similares